Costs and consequences of direct-to-consumer advertising for clopidogrel in medicaid

Archives of Internal Medicine

Volumn 169, Issue 21, 2009, Pages 1969-1974

  Law, Michael R ^a   Soumerai, Stephen B ^b   Adams, Alyce S ^c   Majumdar, Sumit R ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

ARTICLE; CONSUMER; DRUG COST; DRUG MARKETING; HEALTH CARE COST; HEALTH CARE POLICY; MEDICAID; PHARMACY; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

ADVERTISING AS TOPIC; CONSUMER SATISFACTION; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; INFORMATION DISSEMINATION; MASS MEDIA; MEDICAID; PATIENT PARTICIPATION; PHARMACIES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; UNITED STATES;

EID: 73249135536     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.320     Document Type: Article

References (42)

1. Mello MM, Studdert DM, Brennan TA. The pharmaceutical industry versus Medicaid - limits on state initiatives to control prescription-drug costs. New Engl J Med. 2004;350(6):608-613.
2. Catlin A, Cowan C, Heffler S, Washington B. National Health Expenditure Accounts Team National health spending In 2005: the slowdown continues. Health Aff (Millwood). 2007;26(1):142-153.
3. Kaiser Commission on Medicaid and the Uninsured. The continuing Medicaid budget challenge: state Medicaid spending growth and cost containment in fiscal years 2004 and 2005. Kaiser Family Foundation Web site. http://www.kff.org/ medicaid/7190.cfm. Accessed July 9, 2009.
4. Almasi EA, Stafford RS, Kravitz RL, Mansfield PR. What are the public health effects of direct-to-consumer drug advertising? PLoS Med. 2006;3(3):e145.
5. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673-681.
6. Marketing and direct-to-consumer advertising (DTCA) of pharmaceuticals. National Conference of State Legislatures Web site. http://www.ncsl.org/ IssuesResearch/Health/MarketingandAdvertisingofPharmaceuticals2009/tabid/14461/ Default.aspx. Accessed July 9, 2009.
7. Guthrie P. US Congress to consider limits on DTCA. CMAJ. 2007;176(10):1404.
8. Total U.S. promotional spend by type. IMS Health Web site. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/PromotionalSpendChartWebsite.pdf. Accessed July 7, 2009.
9. Morgan S, Mintzes B, Barer M. The economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare? J Health Serv Res Policy. 2003;8(4):237-244.
10. Rosenthal M, Berndt E, Donohue J, Epstein A, Frank R. Demand effects of recent changes in prescription drug promotion. In: Cutler D, Garber A, eds. Frontiers in Health Policy Research. Vol 6. Cambridge, MA: MIT Press; 2003:1-26.
11. DTC at the crossroads: a "direct" hit or miss? IMS Issues and Insights Web site. http://www.imshealthcanada.com/vgn/images/portal/cit- 40000873/15/35/58020533DTCBrochure092204.pdf. Accessed July 7, 2009.
12. Morgan SG. Direct-to-consumer advertising and expenditure on prescription drugs: a comparison of experiences in the United States and Canada. Open Med. 2007;1(1):37-45.
13. Calfee J, Winston C, Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J Law Econ. 2002;45:673-690.
14. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002;324(7332):278-289.
15. Welcome to analysis of ROI for pharmaceutical promotion. RxPromoROI Web site. http://www.rxpromoroi.org/rapp/index.html. Accessed July 9, 2009.
16. Findlay SD. Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers and providers. Pharmacoeconomics. 2001;19(2):109-119.
17. Iizuka T. What explains the use of direct-to-consumer advertising of prescription drugs? J Ind Econ. 2004;52(3):349-379.
18. State drug utilization data. Centers for Medicare and Medicaid Services Web site. http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/List.asp. Accessed July 9, 2009.
19. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-2194.
20. Roughead EE, Zhang F, Ross-Degnan D, Soumerai S. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care. 2006;44(4):378-382.
21. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59(5):540-546.
22. Consumer price index. US Department of Labor Web site. http://www.bls.gov/cpi/. Accessed July 9, 2009.
23. Medicaid managed care enrollment report. Centers for Medicare and Medicaid Services Web site.http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/04- MdManCrEnrllRep.asp. Accessed July 9, 2009.
24. Population estimates. US Census Bureau Web site. http://www.census.gov/ popest/states/states.html. Accessed July 10, 2009.
25. MSIS data Medicaid data sources. Centers for Medicare and Medicaid Services Web site. http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/02- MSISData.asp. Accessed July 20, 2009.
26. Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. Am Heart J. 2008;155(5):904-909.
27. Lied TR, Gonzalez J, Taparanskas W, Shukla T. Trends and current drug utilization patterns of Medicaid beneficiaries. Health Care Financ Rev. 2006;27(3):123-132.
28. TNS Media Intelligence. Ad$ummary. New York, NY: TNS Media Intelligence; 2005.
29. Information on advertising for clopidogrel on network news television. Vanderbilt Television News Archive Web site. http://tvnews.vanderbilt.edu. Accessed April 9, 2008.
30. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
31. The ATC/DDD system. WHO Collaborating Centre for Drug Statistics Methodology Web site. http://www.whocc.no/atcddd/. Accessed July 14, 2009.
32. SAS Institute Inc. SAS 9.1.3 Help and Documentation. Cary, NC: SAS Institute Inc; 2005.
33. Law MR, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ. 2008;337:a1055. doi:10.1136/bmj. a1055.
34. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281(4):380-382.
35. Kelly P. DTC advertising's benefits far outweigh its imperfections. Health Aff (Milwood). 2004(suppl Web exclusives):W4-246-W4-248.
36. Gencarelli D. Average Wholesale Price for Prescription Drugs. Washington, DC: National Health Policy Forum; 2002.
37. Frank RG. Prescription drug prices: why do some pay more than others do? Health Aff (Millwood). 2001;20(2):115-128.
38. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
39. Murray E, Lo B, Pollack L, Donelan K, Lee K. Direct-to-consumer advertising: public perceptions of its effects on health behaviors, health care, and the doctorpatient relationship. J Am Board Fam Pract. 2004;17(1):6-18.
40. Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care. 2005;14(4):246-250.
41. Cassels A. Canada may be forced to allow direct to consumer advertising. BMJ. 2006;332(7556):1469.
42. Meek C. Europe reconsidering DTCA. CMAJ. 2007;176(10):1405.